Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 27, 2026 | Pairidex Closes Over-Subscribed Seed Round to Support the Launch of New Highly Sensitive MRD Test for Leukemia. | The financing brings in $4.89M in new capital to accelerate the commercial launch of FusionMRD™ ST. LOUIS, MO, UNITED STATES, July 27, 2026 /EINPresswire.com/ -- Pairidex, a precision diagnostics company advancing personalized molecular tes... |
| Feb 23, 2026 | Pairidex Secures Lead Investment from BioGenerator Ventures for the Launch of New Highly Sensitive MRD Test for Leukemia | Reducing Uncertainty in the Care and Treatment of Blood Cancer ST. LOUIS, MO, UNITED STATES, February 23, 2026 /EINPresswire.com/ -- Pairidex, an emerging leader in leukemia detection, today announced a lead investment from BioGenerator Ven... |
| Pairidex | “Our proprietary novel droplet digital PCR assay provides personalized, measurable residual disease detection for fusion-driven blood cancers.” |
Reviews 0
FAQ about Pairidex Inc.
What has the press written about Pairidex Inc.?
Parsers VC has collected 4 articles mentioning Pairidex Inc., among them “Pairidex Closes Over-Subscribed Seed Round to Support the Launch of New Highly Sensitive MRD Test for Leukemia.” (Jul 27, 2026) and “Pairidex Secures Lead Investment from BioGenerator Ventures for the Launch of New Highly Sensitive MRD Test for Leukemia” (Feb 23, 2026).
Is Pairidex Inc. still active?
Yes, Pairidex Inc. is active; its latest activity on Parsers VC dates from Sep 22, 2026.